Papers
2
Total Citations
9
H-Index
2
About
Keiji Nihei is a leading Japanese radiation oncologist whose research centers on precision radiotherapy for thoracic and genitourinary malignancies, with a particular focus on minimizing treatment toxicity. His most impactful work investigates extremely hypofractionated radiotherapy (EHF-RT) for early-stage prostate cancer using non-isocentric robotic radiosurgery systems. In his 2016 study, Nihei demonstrated that this technique achieves excellent tumor control while significantly reducing rectal toxicity—a critical advancement that has informed modern prostate cancer management protocols. This work, cited 7 times, remains a foundational reference for stereotactic body radiotherapy (SBRT) in prostate cancer. More recently, Nihei has shaped national clinical standards as a lead author of the Japan Lung Cancer Society’s 2024 Medical Practice Guidelines for lung cancers, including malignant pleural mesothelioma and thymic tumors. His contributions to the thymic epithelial tumors chapter (cited 2 times) establish evidence-based recommendations that unify treatment approaches across Japan. By bridging cutting-edge radiosurgery techniques with rigorous guideline development, Nihei has directly improved patient outcomes and set benchmarks for quality care in radiation oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2